Ilika plc

Ilika plc

IKA.L
Ilika plcGB flagLondon Stock Exchange
28.50
GBp
- -
- -
51.54MMarket Cap
Ilika plc
IKA.L
(London Stock Exchange)

Recent

price

28.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
8.65
0.04
0.05
0.02
0.02
0.02
0.01
0.01
0.03
0.03
0.03
0.02
- -
- -
- -
- -
Revenue per Share
-25.54
-0.08
-0.07
-0.07
-0.05
-0.04
-0.05
-0.05
-0.04
-0.02
-0.03
-0.03
-0.05
-0.05
-0.03
-0.04
Basic EPS, GAAP
-14.62
-0.06
-0.05
-0.08
-0.04
-0.04
-0.05
-0.05
-0.03
-0.03
-0.03
-0.04
-0.07
-0.05
-0.03
-0.04
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-31.19
-0.16
-0.22
-0.25
-0.28
-0.26
-0.31
-0.32
-0.32
-0.29
-0.29
-0.24
-0.26
-0.29
-0.32
-0.35
Book Value per Share
21.12
0.12
0.17
0.07
0.15
0.1
0.05
0.08
0.05
0.06
0.16
0.09
0.19
0.14
0.1
0.08
Tangible Book Value per Share
- -
39
39
48
53
67
67
74
80
96
105
140
153
159
159
159
Basic Weighted Avg Shares
1
2
2
1
1
1
1
1
2
3
3
2
- -
- -
- -
- -
Sales/Revenue/Turnover
-308.01
-206.03
-128.68
-354.69
-295.83
-282.08
-636.98
-374.46
-159.31
-104.01
-117.75
-170.29
-1,636.59
-26,619.82
-31,043.78
-10,286.94
Operating Margin (%)
1
1
1
1
1
- -
- -
- -
- -
- -
1
1
1
2
2
2
Depreciation Expense
-3
-3
-3
-3
-3
-3
-3
-4
-3
-2
-3
-4
-7
-7
-5
-6
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-295.19
-197.28
-146.41
-346.13
-266.52
-246.96
-572.84
-336.95
-141.25
-89.61
-108.7
-156.36
-1,436.91
-21,585.8
-23,947.26
-8,030.2
Profit Margin (%)
1
3
5
2
7
6
3
6
3
4
16
11
24
18
13
9
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
- -
- -
- -
LT Debt
3
5
7
3
8
7
3
6
4
6
17
14
31
25
20
17
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
29.35%
9.89%
-15.62%
Free Cash Flow
16.83%
26.89%
52.29%
Net Income, GAAP
13.27%
21.45%
22.62%
Sales/Revenue/Turnover
19.33%
6.67%
265.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.03
2025
- -
- -
- -
- -
-0.04
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Ilika plc (LSE: IKA), a pioneer in solid-state battery technology headquartered in Romsey, UK and founded in 2004 as a spin-out from the University of Southampton, develops and commercialises next-generation batteries for MedTech, Industrial IoT, electric vehicles and consumer electronics applications. The company offers two core product lines: Stereax miniature solid-state batteries, which provide high energy density, fast charging, long cycle life and non-flammable safety for powering mm-scale active implantable medical devices such as neurostimulators, smart orthopaedics, orthodontics and biometric sensors, as well as industrial wireless sensors; and Goliath large-format solid-state batteries featuring oxide electrolytes and silicon anodes for electric vehicles and cordless consumer appliances, delivering enhanced range, rapid charging, reduced weight and superior safety over conventional lithium-ion cells. Ilika operates primarily from the UK with global customer engagement across Asia, Europe and North America, generating revenue through grant-funded development, customer evaluation prototypes, technology licensing and manufacturing partnerships. Recent developments include the transfer of Stereax manufacturing operations to US partner Cirtec Medical LLC under a 10-year licensing agreement signed in 2023, enabling commercial sample production targeted for late 2025 and supporting a pipeline of 21 medical device customers; completion of the £8.2 million HISTORY project with BMW and Fortescue Zero delivering a 50Ah Goliath prototype; execution of the £2.7 million SiSTEM project with Mpac plc, UKBIC and Tata subsidiary Agratas, adding 1.5 MWh annual pilot assembly capacity; a bilateral technology collaboration and heads of terms with Agratas for potential gigafactory-scale partnership; a post-period £4.2 million fundraising in June 2025; and a £1.25 million grant award from the Advanced Propulsion Centre's DRIVE35 PRIMED programme commencing August 2025 with HSSMI and UKBIC to produce Goliath A-samples on industrial equipment.